Navigation Links
FDA Approves New Treatment Option for Late-Stage Breast Cancer
Date:11/15/2010

SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute.  This year, an estimated 207,090 women will be diagnosed with breast cancer, while 39,840 women will die from the disease.

Halaven is a synthetic form of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai. This injectable therapy is a microtubule inhibitor, believed to work by inhibiting cancer cell growth. Before receiving Halaven, patients should have received prior anthracycline- and taxane-based chemotherapy for early or late-stage breast cancer.

Halaven's safety and effectiveness were established in a single study in 762 women with metastatic breast cancer who had received at least two prior chemotherapy regimens for late-stage disease. Patients were randomly assigned to receive treatment with either Halaven or a different single agent therapy chosen by their oncologist.

The study was designed to measure the length of time from when this treatment started until a patient's death (overall survival). The median overall survival for patients receiving Halaven was 13.1 months compared with 10.6 months for those who received a single agent therapy.

"There are limited treatment options for women with aggressive forms of late-stage breast cancer who have already received other therapies," said Richard Pazdur, M.D., direct
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... DIEGO , Oct. 21, 2014   ... today the latest genomics research centers to purchase ... Salk Institute, the National Cancer Institute (NCI), NIH ... Sequencing Center). Before Irys, obtaining a comprehensive view ... next generation sequencing (NGS) does not deliver the ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... synthetic immunogens against cancers and infectious diseases, announced today ... Development Agreement (CRADA) with the United States Department of ... Animal Disease Center. This collaboration will evaluate the efficacy ...
... Co., Inc. (NYSE Amex: TPI ), a pharmaceutical ... branded generics and other pharmaceuticals, announced the financial results for ... year 2011 ending June 30 ... delivered $95.2 million, exceeding the guided $90.0 million revenue forecast ...
Cached Medicine Technology:Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4TPI Reports Fiscal Year 2011 Financial Results 2TPI Reports Fiscal Year 2011 Financial Results 3TPI Reports Fiscal Year 2011 Financial Results 4TPI Reports Fiscal Year 2011 Financial Results 5TPI Reports Fiscal Year 2011 Financial Results 6TPI Reports Fiscal Year 2011 Financial Results 7TPI Reports Fiscal Year 2011 Financial Results 8TPI Reports Fiscal Year 2011 Financial Results 9TPI Reports Fiscal Year 2011 Financial Results 10TPI Reports Fiscal Year 2011 Financial Results 11
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
(Date:10/22/2014)... Thompson HealthDay Reporter TUESDAY, Oct. ... with Ebola while working for NBC News in Liberia ... special isolation unit at Nebraska Medical Center in Omaha, where he ... Tuesday. A blood test confirmed by the U.S. Centers for ... home to Providence, R.I., NBC News reported Tuesday night. ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... Prix Galien USA Names HUMIRA Best Biotechnology Product, ... (NYSE:,ABT), a leader in the treatment of autoimmune ... Biotechnology Product for HUMIRA (R),(adalimumab), the first approved ... the treatment of moderate to severe rheumatoid arthritis,psoriatic ...
... Powerful New Combination Treatment Option Reduces Mean Systolic Blood ... ... Sept. 27, 2007 Daiichi Sankyo, Inc.,announced today that the ... and olmesartan medoxomil) for the,treatment of hypertension, also known as ...
... CHURCH, Va., Sept. 27 The National,Legal and Policy ... General Motors (GM) and the United Auto Workers (UAW) ... to a fund,controlled by the union., Dr. Carl ... of Union Corruption Update, reacted by saying, "This is,a ...
... Fastest ... Southeast ... Michigan, PONTIAC, Mich., Sept. 27 Continuing its status ... Care is pleased to announce the addition of POH Medical,Center to its network of ...
... Krimpets Will Benefit Online ... Support and Information, PHILADELPHIA, Sept. 27 Tasty ... the,Tastykake Strawberry Jelly Krimpet. 10% of the proceeds from ... to breastcancer.org, a,Narberth, Pennsylvania based online resource dedicated to ...
... Says NCPA Study, DALLAS, Sept. 27 The ... so rapidly that these benefits,are now the fastest rising ... the rate of retirement benefits, according to a new,analysis ... a separate,study also released today, the NCPA says Chile,s ...
Cached Medicine News:Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 2Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 3Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 4Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 2Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 3Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 4Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 6Health News:McLaren Health Care Adds POH Medical Center to System 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 3Health News:Disability System Sorely in Need of Reform 2Health News:Disability System Sorely in Need of Reform 3
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... Faster speeds, highest precision, more ... flexible concept: this is the definition of ... few years nucleic acid research has been ... capabilities required of PCR Systems. To ...
... The Techne TC412 is a high performance, high ... Features & Benefits include: Flexible block ... programming, 8 peltiers, PC networking. Includes a ... to 32 Techne cyclers can be connected and ...
... The Tetrad 2 thermal cycler incorporates ... Research Tetrad chassis. As before, the chassis ... power supply is internal, while a large, color ... yet, updated automatic lids -- Moto Alphas -- ...
Medicine Products: